Belite Bio (BLTE) Intangibles (2024 - 2025)
Belite Bio's (BLTE) quarterly Intangibles came in at $19000.0 in Q4 2025, down 38.71% year-on-year from $31000.0 in Q4 2024, and down 20.83% quarter-over-quarter from $24000.0 in Q3 2025.
Belite Bio (BLTE) Intangibles (2024 - 2025) Analysis & Trends
Belite Bio's Intangibles history runs 2 years deep, the most recent figure standing at $19000.0 for Q4 2025.
- On a quarterly basis, Intangibles fell 38.71% year-over-year to $19000.0 in Q4 2025; TTM through Dec 2025 was $19000.0, a 38.71% decrease from a year earlier, with the FY2025 full-year figure at $19000.0, down 38.71% from the prior year.
- Intangibles slipped to $19000.0 in Q4 2025 per BLTE's latest filing, from $24000.0 in the prior quarter.
- Across five years, Intangibles topped out at $31000.0 in Q4 2024 and bottomed at $19000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 16.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 11,640.44 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 61.68 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 418.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.29 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 55.80 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Dec 31, 2024 | 31,000.00 |